海正药业 - Financials

海正药业 — Financial Statements

Annual Quarterly

5 10 All

Income Statement

Balance Sheet

Cash Flow

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	10.3B	10.1B	11.4B	11.6B	11.4B
Revenue Growth %	2.9%	-11.7%	-1.7%	1.9%	--
Total Revenue	10.3B	10.1B	11.4B	11.6B	11.4B
Cost Of Revenue	6.0B	5.9B	6.3B	6.6B	6.4B
+Gross Profit	4.4B	4.2B	5.0B	4.9B	4.9B
Gross Margin %	42.5%	41.5%	44.2%	42.7%	43.3%
Total Operating Cost	9.9B	10.1B	10.7B	11.1B	10.8B
Selling Expenses	2.1B	2.4B	2.4B	2.5B	2.5B
Admin Expenses	897.0M	909.0M	1.1B	996.0M	910.0M
Rd Expenses	358.0M	392.0M	429.0M	373.0M	401.0M
Finance Expenses	129.0M	192.0M	263.0M	331.0M	413.0M
+Operating Income	721.0M	89.4M	682.0M	700.0M	777.0M
Operating Margin %	7.0%	0.9%	6.0%	6.0%	6.8%
Non Operating Income	7.5M	1.7M	8.5M	20.7M	147.0M
Non Operating Expenses	10.7M	174.0M	7.5M	76.5M	19.4M
Investment Income	157.0M	74.3M	31.1M	104.0M	34.4M
Fair Value Change Income	-14.9M	278,300	-107.0M	-17.8M	731,400
Asset Disposal Income	722,700	-11.5M	-496,500	-20.6M	34.4M
Asset Impairment Loss	219.0M	286.0M	126.0M	109.0M	75.3M
Other Income	114.0M	105.0M	101.0M	117.0M	149.0M
Income Before Tax	718.0M	-82.9M	683.0M	644.0M	904.0M
Income Tax	127.0M	14.1M	192.0M	133.0M	181.0M
+Net Income	591.0M	-97.0M	491.0M	511.0M	723.0M
Net Margin %	5.7%	-1.0%	4.3%	4.4%	6.4%
Net Income Attributable	601.0M	-93.2M	489.0M	487.0M	417.0M
Minority Interest	-9.9M	-3.8M	2.4M	23.7M	306.0M
Eps Basic	0.52	-0.08	0.42	0.43	0.43
Eps Diluted	--	--	--	--	--

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	1.5B	1.6B	1.4B	1.3B	2.1B
Trading Financial Assets	--	292,600	--	3.1M	357,600
Accounts Receivable	1.8B	1.9B	2.5B	2.1B	1.6B
Notes Receivable	--	--	--	--	36.2M
Notes And Accounts Receivable	1.8B	1.9B	2.5B	2.1B	1.7B
Prepayments	177.0M	214.0M	255.0M	226.0M	278.0M
Inventory	1.8B	2.0B	1.9B	2.0B	2.6B
Total Current Assets	5.7B	6.4B	6.4B	6.4B	7.3B
Long Term Equity Investment	1.4B	1.4B	1.5B	1.3B	1.1B
Fixed Assets	--	7.5B	7.8B	8.2B	8.1B
Fixed Assets Total	7.3B	7.5B	7.8B	8.2B	8.1B
Construction In Progress	--	688.0M	1.2B	1.5B	2.3B
Construction In Progress Total	217.0M	688.0M	1.2B	1.5B	2.3B
Intangible Assets	947.0M	1.1B	1.3B	1.4B	734.0M
Long Term Deferred Expenses	5.3M	8.6M	10.7M	13.2M	14.5M
Total Non Current Assets	10.3B	11.3B	12.4B	13.0B	13.5B
Total Assets	16.0B	17.6B	18.8B	19.4B	20.9B
Short Term Borrowings	2.2B	2.2B	2.4B	4.0B	5.1B
Accounts Payable	882.0M	868.0M	1.0B	1.0B	1.4B
Advance Receipts	--	40,000	--	--	419,200
Contract Liabilities	91.5M	106.0M	119.0M	268.0M	248.0M
Total Current Liabilities	6.1B	6.6B	7.1B	8.8B	10.5B
Long Term Borrowings	1.0B	1.1B	1.6B	1.3B	1.1B
Total Non Current Liabilities	1.3B	2.7B	3.3B	3.2B	2.1B
Total Liabilities	7.4B	9.3B	10.4B	12.0B	12.6B
Paid In Capital	1.2B	1.2B	1.2B	1.2B	966.0M
Capital Reserve	4.3B	4.3B	4.2B	3.5B	3.6B
Surplus Reserve	599.0M	554.0M	516.0M	465.0M	402.0M
Retained Earnings	2.5B	2.0B	2.3B	2.0B	1.6B
Minority Equity	238.0M	247.0M	251.0M	42.2M	1.6B
Equity Attributable	8.3B	8.1B	8.1B	7.3B	6.7B
Total Equity	8.6B	8.3B	8.3B	7.3B	8.3B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	11.1B	10.5B	11.5B	11.7B	11.5B
Tax Refunds Received	27.6M	43.0M	162.0M	66.7M	99.5M
Total Operating Cash Inflow	11.5B	10.9B	12.1B	12.1B	12.1B
Cash Paid For Goods	5.2B	4.9B	5.0B	5.6B	6.0B
Cash Paid To Employees	1.6B	1.7B	1.7B	1.6B	1.4B
Taxes Paid	654.0M	687.0M	829.0M	734.0M	393.0M
Total Operating Cash Outflow	9.3B	9.5B	10.0B	10.3B	10.5B
Operating Cash Flow	2.2B	1.5B	2.2B	1.8B	1.6B
Total Investing Cash Inflow	450.0M	662.0M	725.0M	2.2B	4.5B
Total Investing Cash Outflow	741.0M	955.0M	1.4B	2.8B	3.5B
Investing Cash Flow	-290.0M	-293.0M	-665.0M	-516.0M	1.0B
Cash From Borrowings	4.1B	3.8B	4.6B	6.6B	6.8B
Dividends And Interest Paid	148.0M	356.0M	381.0M	417.0M	613.0M
Debt Repayments	4.3B	3.8B	6.2B	8.9B	7.2B
Total Financing Cash Inflow	4.4B	3.9B	6.1B	8.7B	7.4B
Total Financing Cash Outflow	6.4B	4.9B	7.6B	10.7B	9.6B
Financing Cash Flow	-2.0B	-1.0B	-1.5B	-2.1B	-2.2B
Net Change In Cash	-140.0M	164.0M	-11.9M	-831.0M	348.0M
Ending Cash Balance	1.2B	1.3B	1.2B	1.2B	2.0B
Capex	238.0M	240.0M	531.0M	622.0M	692.0M